Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may forecast cancer return in rare blood disease

NCT ID NCT04893564

First seen Nov 01, 2025

Summary

This study is looking at whether small pieces of tumor DNA found in the blood after treatment can predict if Waldenström Macroglobulinemia will come back. Researchers will follow 90 patients for up to 3 years after their first 6 months of therapy. The goal is to see if this DNA test can help doctors know who needs closer monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Amiens

    RECRUITING

    Amiens, 80480, France

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors predict which patients are at higher risk of relapse, allowing for earlier intervention.

What could go wrong

This is an observational study, not a treatment trial. It may not lead to any change in patient care, and results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.